Predictive Value of UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity and Therapeutic Efficacy in Colorectal Cancer Patients

Page 39 of 46 Predictive Value of UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity and Therapeutic Efficacy in Colorectal Cancer Patients Qianqian Yu1, Zhihuan Li2, Xiaoqi Nie1, Lu Wang1, Chen Gong1, Bo Liu1, Xin Liao3, Ben Zhao1, Qianxia Li1, Mingsheng Zhang1, Hong Qiu1, Xianglin Yuan1* 1Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China. 2Dongguan Enlife Stem Cell Biotechnology Institute, Dongguan 523000, Guangdong, China 3Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China

[1]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Higuchi,et al.  Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer , 2019, Gastric Cancer.

[3]  A. Barnadas,et al.  Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype , 2018, British Journal of Cancer.

[4]  Astrid Gall,et al.  Ensembl 2019 , 2018, Nucleic Acids Res..

[5]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[6]  F. Huang,et al.  UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan‐induced toxicity: A meta‐analysis , 2018, Asia-Pacific journal of clinical oncology.

[7]  C. Xie,et al.  UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy , 2018, Cancer Chemotherapy and Pharmacology.

[8]  L. Boni,et al.  DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer , 2017, Oncotarget.

[9]  Jiao-Er Zhang,et al.  UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis , 2017, Cancer Chemotherapy and Pharmacology.

[10]  W. Duan,et al.  Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy , 2017, Journal of Cancer.

[11]  Marco Peters,et al.  Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses , 2016, The Pharmacogenomics Journal.

[12]  F. Innocenti,et al.  Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer , 2016, Clinical Cancer Research.

[13]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[14]  N. Zhou,et al.  UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer , 2016, Cancer Chemotherapy and Pharmacology.

[15]  H. Qiu,et al.  Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy. , 2016, World journal of gastroenterology.

[16]  D. Pezet,et al.  High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT) , 2016, Annals of Surgical Oncology.

[17]  Y. Sasaki,et al.  Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. , 2015, World journal of gastroenterology.

[18]  L. Dean.  Irinotecan Therapy and UGT1A1 Genotype , 2015 .

[19]  M. Loriot,et al.  UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice , 2015, Fundamental & clinical pharmacology.

[20]  M. Peake,et al.  Stage at diagnosis and early mortality from cancer in England , 2015, British Journal of Cancer.

[21]  Soma Das,et al.  Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Pignon,et al.  The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis , 2014, The Pharmacogenomics Journal.

[23]  Yali Lv,et al.  Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients , 2014, Cancer Chemotherapy and Pharmacology.

[24]  Ming Li,et al.  UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians , 2014, Cancer Chemotherapy and Pharmacology.

[25]  Qing Xu,et al.  Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai , 2013, Journal of Cancer Research and Clinical Oncology.

[26]  L. Shen,et al.  UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients , 2013, Medical Oncology.

[27]  Xiang Liu,et al.  Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians , 2013, The Pharmacogenomics Journal.

[28]  Geoffrey Liu,et al.  Association between UGT1A1*28 Polymorphisms and Clinical Outcomes of Irinotecan-Based Chemotherapies in Colorectal Cancer: A Meta-Analysis in Caucasians , 2013, PloS one.

[29]  E. Bandrés,et al.  Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan , 2011, The Pharmacogenomics Journal.

[30]  S. Gruber,et al.  Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients , 2011, Cancer.

[31]  A. Carrato,et al.  UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy , 2010, British Journal of Cancer.

[32]  C. Strassburg.  Gilbert-Meulengracht’s syndrome and pharmacogenetics: is jaundice just the tip of the iceberg? , 2010, Drug metabolism reviews.

[33]  J. Crowley,et al.  Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Litwin,et al.  Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors , 2009, Cancer Chemotherapy and Pharmacology.

[35]  Jin-Hwang Liu,et al.  UGT1A1*28 polymorphism predicts irinotecan‐induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma , 2008, Cancer.

[36]  Teruhiko Yoshida,et al.  Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28 , 2007, Pharmacogenetics and genomics.

[37]  J. Panetta,et al.  UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Shih-Ming Huang,et al.  Molecular pathogenesis of Gilbert's syndrome: decreased TATA-binding protein binding affinity of UGT1A1 gene promoter , 2007, Pharmacogenetics and genomics.

[39]  M. Narabayashi,et al.  Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN‐38 glucuronidation in Japanese patients with cancer , 2006, Cancer science.

[40]  Giuseppe Toffoli,et al.  The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  V. Georgoulias,et al.  Irinotecan (CPT-11) in Combination With Infusional 5-Fluorouracil and Leucovorin (de Gramont Regimen) as First-Line Treatment in Patients With Advanced Colorectal Cancer: A Multicenter Phase II Study , 2002, American journal of clinical oncology.

[42]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[43]  E. Beutler,et al.  Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Ratain,et al.  Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.

[45]  W. Rubinstein,et al.  Irinotecan Therapy and UGT1A1 Genotype -- Medical Genetics Summaries , 2012 .

[46]  M. Stauch,et al.  Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. , 2011, European journal of cancer.

[47]  Yoshiro Saito,et al.  Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. , 2003, Drug metabolism and disposition: the biological fate of chemicals.